Neutralizing interleukin-13 increases skin microbial diversity: Results from a phase 3, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis

被引：0
|
作者：
Bieber, Thomas [1 ]
Beck, Lisa A. [2 ]
Pink, Andrew [3 ]
Saeki, Hidehisa [4 ]
Eichenfield, Lawrence [5 ,6 ]
Werfel, Thomas [7 ]
Rosholm, Anders [8 ]
Ropke, Mads [8 ]
Paller, Amy [9 ]
机构：
[1] Univ Hosp Bonn, Bonn, Germany
[2] Univ Rochester, Med Ctr, Dept Dermatol, Rochester, NY 14627 USA
[3] Guys & St Thomas Hosp, St Johns Inst Dermatol, London, England
[4] Nippon Med Sch, Dept Dermatol, Tokyo, Japan
[5] Univ Calif San Diego, Sch Med, Dept Dermatol, La Jolla, CA 92093 USA
[6] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA
[7] Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany
[8] LEO Pharma AS, Ballerup, Denmark
[9] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Evanston, IL 60208 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
28170
引用
收藏
页码：AB177 / AB177
页数：1
相关论文
共 50 条
  • [1] Neutralizing interleukin-13 increases skin microbial diversity: results from a phase III, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis
    Bieber, T.
    Beck, L. A.
    Pink, A.
    Saeki, H.
    Eichenfield, L.
    Werfel, T.
    Rosholm, A.
    Ropke, M.
    Paller, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E111 - E112
  • [2] Neutralization of Interleukin-13 increases Skin microbial Diversity: Results of a randomized, double-blind, placebo-controlled Phase III Trial of Tralokinumab in adult Patients with Atopic Dermatitis
    Bieber, Thomas
    Beck, Lisa A.
    Pink, Andrew
    Saeki, Hidehisa
    Eichenfield, Lawrence
    Werfel, Thomas
    Ropke, Mads
    Paller, Amy
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 18 - 18
  • [3] Impact of targeting interleukin-13 on Staphylococcus aureus colonization: results from a phase III, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis
    Bieber, T.
    Beck, L. A.
    Pink, A.
    Saeki, H.
    Eichenfield, L.
    Werfel, T.
    Rosholm, A.
    Roepke, M.
    Paller, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E112 - E112
  • [4] The targeted Action on Interleukin-13 with Tralokinumab improved the Sleep in two randomized, double-blind, placebo-controlled Phase III Studies in Patients with atopic Dermatitis
    Simon, J. C.
    Barbarot, S.
    Gooderham, M.
    Simpson, E.
    Kurbasic, A.
    Olsen, C. K.
    Cork, M. J.
    Silverberg, J., I
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 56 - 56
  • [5] Specifically targeting interleukin-13 with tralokinumab improved sleep in two phase III, randomized, double-blind, placebo-controlled trials in patients with atopic dermatitis
    Silverberg, J. I.
    Barbarot, S.
    Gooderham, M.
    Simon, J. C.
    Simpson, E.
    Kurbasic, A.
    Olsen, C. K.
    Cork, M. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E64 - E65
  • [6] Influence of Targeting of Interleukin-13 on Colonization with Staphylococcus aureus: Results of a randomized, double-blind, placebo controlled Phase III Study with Tralokinumab in Adult Patients with Atopical Dermatitis
    Bieber, T.
    Beck, L. A.
    Pink, A.
    Saeki, H.
    Eichenfield, L.
    Rosholm, A.
    Roepke, M.
    Paller, A.
    Werfel, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 66 - 67
  • [7] Safety of specifically targeting interleukin-13 with tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase III and phase II trials
    Simpson, E.
    Merola, J. F.
    Silverberg, J. I.
    Zachariae, R.
    Olsen, C. K.
    Wollenberg, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E66 - E66
  • [8] DUPILUMAB TREATMENT IN PATIENTS WITH ATOPIC HAND AND FOOT DERMATITIS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Simpson, Eric L.
    Silverberg, Jonathan I.
    Worm, Margitta
    Honari, Golara
    Masuda, Koji
    Schuttelaar, Marie-Louise A.
    Maloney, Jennifer
    Xiao, Jing
    Dubost-Brama, Ariane
    Bansal, Ashish
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 53 - 54
  • [9] Dupilumab treatment in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial
    Simpson, Eric L.
    Silverberg, Jonathan, I
    Worm, Margitta
    Honari, Golara
    Masuda, Koji
    Sygula, Ewa
    Maloney, Jennifer
    Mannent, Leda P.
    Xiao, Jing
    Dubost-Brama, Ariane
    Bansal, Ashish
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [10] Dupilumab treatment in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
    Simpson, E.
    Silverberg, J.
    Worm, M.
    Honari, G.
    Masuda, K.
    Sygula, E.
    Maloney, J.
    Mannent, L.
    Xiao, J.
    Dubost-Brama, A.
    Bansal, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S350 - S350
12345